Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obesity Drugs Covered By One-Third Of Large Employers In Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

The National Business Group on Health survey illustrates the continuing reimbursement challenges faced by the recently introduced obesity drugs Qsymia and Belviq.

You may also be interested in...



With Another Push From Eisai, Can Arena’s Belviq Be A Blockbuster?

The Japanese pharma has expanded its collaboration with Arena for the obesity treatment Belviq, but the drug is off to a slow start in a market full of non-starters.

Japan Earnings Highlights: New Products Win The Day For Top Pharma

PharmAsia News brings highlights from Japan’s week of earnings presentations.

Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking

The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel